• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 957127 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416586003 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416586003 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Acadia Pharmaceuticals Bullish Moving Average Crossover Alert (ACAD)

Published on Thu, 05/15/2014 - 13:19
By Peter Chu

Today, shares of Acadia Pharmaceuticals (NASDAQ:ACAD) have crossed bullishly above their 10-day moving average of $19.04 on a volume of 954K shares. This may provide swing traders with an opportunity for a long position, as such a crossover often suggests higher prices in the near term.

Acadia Pharmaceuticals share prices have moved between a 52-week high of $32.00 and a 52-week low of $11.81 and are now trading 63% above that low price at $19.23 per share. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 2.6%.

Acadia Pharmaceuticals has overhead space with shares priced $19.23, or 42.1% below the average consensus analyst price target of $33.20. The stock should run into initial resistance at its 50-day moving average (MA) of $22.47 and subsequent resistance at its 200-day MA of $23.17.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Next Resistance Level for O'Reilly Autom...

O'Reilly Automotive (NASDAQ:ORLY) has opened bullishly above the pivot of $178.43 today ...

Stock Investors Bid Up Shares of Century...

Century Aluminum (NASDAQ:CENX) is one of today's notable stocks on the rise, up 6.2% to ...

Next Resistance Level for Ameriprise Fin...

Ameriprise Financial (NYSE:AMP) has opened bullishly above the pivot of $130.18 today a ...

Shares of Aluminum of China Receive a Bo...

One of today's stocks on the move is Aluminum of China (NYSE:ACH), up 6.3% to $11.17. ...

Next Resistance Level for DENTSPLY Inter...

Shares of DENTSPLY International (NASDAQ:XRAY) have bullishly opened above the pivot of ...

Stock Investors Bid Up Shares of Autodes...

One of today's notable stocks on the rise is Autodesk (NASDAQ:ADSK), up 6.7% to $62.33. ...

Next Resistance Level for Bemis (BMS) is...

Shares of Bemis (NYSE:BMS) opened today above their pivot of $39.12 and have already re ...

Shares of Ross Stores Receive a Boost, U...

Ross Stores (NASDAQ:ROST) is a company whose shares are active, trading 6.7% higher to ...